Neutralising antibody escape of SARS‐CoV‐2 spike protein: risk assessment for antibody‐based Covid‐19 therapeutics and vaccines
The Spike protein is the target of both antibody‐based therapeutics (convalescent plasma,
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …
[HTML][HTML] The emerging concern and interest SARS-CoV-2 variants
E Janik, M Niemcewicz, M Podogrocki, I Majsterek… - Pathogens, 2021 - mdpi.com
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for
coronavirus disease 2019 (COVID-19) was discovered in December 2019 in Wuhan, China …
coronavirus disease 2019 (COVID-19) was discovered in December 2019 in Wuhan, China …
Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) Spike mutation T478K
S Di Giacomo, D Mercatelli… - Journal of medical …, 2021 - Wiley Online Library
Several severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants have
emerged, posing a renewed threat to coronavirus disease 2019 containment and to vaccine …
emerged, posing a renewed threat to coronavirus disease 2019 containment and to vaccine …
Predicting the mutational drivers of future SARS-CoV-2 variants of concern
SARS-CoV-2 evolution threatens vaccine-and natural infection–derived immunity and the
efficacy of therapeutic antibodies. To improve public health preparedness, we sought to …
efficacy of therapeutic antibodies. To improve public health preparedness, we sought to …
[HTML][HTML] Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
Understanding SARS-CoV-2 evolution and host immunity is critical to control COVID-19
pandemics. At the core is an arms-race between SARS-CoV-2 antibody and angiotensin …
pandemics. At the core is an arms-race between SARS-CoV-2 antibody and angiotensin …
[HTML][HTML] SARS-CoV-2 variant of concern 202012/01 has about twofold replicative advantage and acquires concerning mutations
The novel SARS-CoV-2 Variant of Concern (VOC)-202012/01 (also known as B. 1.1. 7), first
collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in …
collected in United Kingdom on 20 September 2020, is a rapidly growing lineage that in …
[HTML][HTML] An engineered bispecific human monoclonal antibody against SARS-CoV-2
Z Li, S Li, G Zhang, W Peng, Z Chang, X Zhang… - Nature …, 2022 - nature.com
The global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
requires effective therapies against coronavirus disease 2019 (COVID-19), and neutralizing …
Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B. 1.617. 2 and implications for immune evasion
Following the initial surges of the Alpha (B. 1.1. 7) and the Beta (B. 1.351) variants, a more
infectious Delta variant (B. 1.617. 2) is now surging, further deepening the health crises …
infectious Delta variant (B. 1.617. 2) is now surging, further deepening the health crises …
[HTML][HTML] Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
Since the emergence of the first case of coronavirus disease 2019 (COVID-19), caused by
severe acute respiratory syndrome coronavirus (SARS-CoV-2), the viral genome has …
severe acute respiratory syndrome coronavirus (SARS-CoV-2), the viral genome has …
[HTML][HTML] Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo
Z Zhang, E Zeng, L Zhang, W Wang, Y Jin, J Sun… - Cell Discovery, 2021 - nature.com
The current COVID-19 pandemic, caused by SARS-CoV-2, poses a serious public health
threat. Effective therapeutic and prophylactic treatments are urgently needed. Angiotensin …
threat. Effective therapeutic and prophylactic treatments are urgently needed. Angiotensin …